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ABSTRACT
Recombinant adenoviruses containing a double-
stranded DNA genome of 26–45 kb were broadly ex-
plored in basic virology, for vaccination purposes,
for treatment of tumors based on oncolytic virother-
apy, or simply as a tool for efficient gene transfer.
However, the majority of recombinant adenoviral vec-
tors (AdVs) is based on a small fraction of aden-
ovirus types and their genetic modification. Recom-
bineering techniques provide powerful tools for ar-
bitrary engineering of recombinant DNA. Here, we
adopted a seamless recombineering technology for
high-throughput and arbitrary genetic engineering of
recombinant adenoviral DNA molecules. Our cloning
platform which also includes a novel recombination
pipeline is based on bacterial artificial chromosomes
(BACs). It enables generation of novel recombinant
adenoviruses from different sources and switching
between commonly used early generation AdVs and
the last generation high-capacity AdVs lacking all vi-
ral coding sequences making them attractive candi-
dates for clinical use. In combination with a novel re-
combination pipeline allowing cloning of AdVs con-
taining large and complex transgenes and the possi-
bility to generate arbitrary chimeric capsid-modified
adenoviruses, these techniques allow generation of
tailored AdVs with distinct features. Our technolo-
gies will pave the way toward broader applications of
AdVs in molecular medicine including gene therapy
and vaccination studies.
INTRODUCTION
To broadly study biological and clinical features of large
DNA viruses, efficient generation of genetically modified
viral DNA molecules is mandatory. Adenoviruses are non-
enveloped double-stranded DNA viruses and more than 60
human adenoviruses types with different type-dependent
clinical pictures were identified. Recombinant adenoviruses
were broadly explored in various applications including
vaccination studies, oncolytic virotherapy and therapeutic
gene transfer. However, limitations of currently used recom-
binant adenoviruses, especially those which were employed
in preclinical and clinical trials, originate in the limited num-
ber of distinct adenovirus types which are available as vec-
tors and the limited possibilities to modify the available vec-
tor backbones.
Most adenoviral vectors (AdVs) are based on the hu-
man adenovirus type 5 with a distinct tropism and a high
sero-prevalence strongly limiting the usage of these vectors
(1,2). For construction of early generation vectors associ-
ated with cellular toxicity due to induction of innate and
adoptive immune responses, the early gene region E1 or in
addition the early regions E2, E3 or E4 were replaced by
the genetic cargo sequence (3). In contrast, newest genera-
tion high-capacity adenoviral vectors (HCAdV) are devoid
of all viral coding sequences (4–6). Their production is de-
pendent on a helper virus (HV), which provides viral cap-
sid proteins in trans for efficient capsid assembly and re-
lease of viral particles. However, packaging of helper virus
genomes is inhibited due to recombinase-mediated excision
of the packaging signal. This enables packaging of HCAdV
genomes containing cargo sequences flanked by minimal 5′
and 3′ sequences of the adenoviral genome with a maxi-
mized capacity for cargo sequences (up to 36 kb) and re-
duced vector-related toxicity and immune responses (7–9).
Thus, HCAdVs represent attractive tools for gene and cell
therapy as well as for vaccination approaches and basic re-
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search applications. Due to their large genome they offer
new perspectives regarding applications for transfer of com-
plex expression systems such as inducible systems or trans-
genes under control of endogenous regulatory sequences.
In addition, a limited amount of capsid-modulations was
exploited utilizing early generation AdVs allowing signifi-
cant improvements in transduction efficiencies for specific
cell types, in vivo targeting and escape from neutralizing
anti-adenoviral antibodies (10,11). However, up to now the
full potential of HCAdV was not accessible due to the ma-
jor challenge of cloning and modulating HCAdV and HV
genomes.
For improving biological, preclinical and clinical features
of recombinant adenoviruses, the establishment of molec-
ular methods allowing high-throughput genetic manipula-
tion of virus genomes is mandatory. Currently used meth-
ods for genetic manipulation of adenoviruses are based on
either rare endonucleases or homologous recombination
in mammalian cells or bacteria of Escherichia coli strain
BJ5183, which constitutively express  recombinases (12–
14). However, these methods are work-intensive and time-
consuming. Moreover, generation is dependent on com-
plex constructions of intermediate clones containing ei-
ther respective endonuclease binding sites or long homol-
ogous sequences (>200 bp) (15). Previously, an elegant
recombination-mediated genetic engineering (recombineer-
ing) method was established allowing traceless modification
of bacterial artificial chromosomes (BACs). Herein, modi-
fications were incorporated by two successive homologous
recombinations at high efficiencies (16) based on the selec-
tion marker galK which can be used for positive and nega-
tive selection. In this system, recombinases are encoded en-
dogenously by bacteria of E. coli strain SW102, which ex-
press high levels upon heat-induction. In contrast to pre-
vious methods, small homologous regions (<50 bp) are
sufficient for efficient recombination, which can be gener-
ated by PCR utilizing adequate primers. Therefore, time-
consuming and challenging construction of intermediate
clones containing the modified sequence flanked by long
homologies or endonuclease binding sites can be avoided.
In a previous study it was shown that this technique works
efficiently for inserting transgenes into early generation vec-
tors (17). Here, we adopted this recombineering technique
for high-throughput generation of AdVs including HCAdV
and HV facilitating development of novel vectors with im-
proved features.
MATERIALS AND METHODS
Cloning of complete adenoviral vector genomes from different
sources
For cloning of complete adenoviral genomes we adopted
a DNA recombination method. This technology only re-
quires short homology arms (50 bp) which can for in-
stance be linked to a PCR primer. A first description of
this methodology for modulation of BACs is provided in
a previous publication (16). In brief, this method is based
on SW102 strain of E. coli in which  recombinases can
be induced by heat shock at 42◦C for 15 min. After this
heat shock, SW102 bacteria containing the target BAC can
be used for preparation of electro-competent cells and 1.5
g of the linear DNA for homologous recombination can
be transformed into these bacteria. For isolation of single
clones, bacteria were selected on agar plates containing the
respective selection marker.
As a first option for cloning of complete adenoviral
genomes, purified adenovirus particles can be used. These
particles were isolated from crude cell lysate containing am-
plified adenovirus by caesium chloride (CsCl) gradients. Ac-
cording to our previous publication (6), a step gradient and
continuous CsCl gradient were performed. For removal of
CsCl a dialysis was performed as described previously (6).
Final vector aliquots were stored at −80◦C until usage. Af-
ter titration (6), viral DNA was isolated from 2 to 4 ×
1010 purified adenoviral particles. After proteinase K digest
a phenol–chloroform extraction was performed and aden-
oviral DNA precipitated by ice-cold 100% ethanol. After a
washing step with 70% ethanol, adenoviral DNA was dis-
solved in H2O. It is of note that for all steps required for
DNA isolation from virions shearing of the DNA should
be avoided by treating the DNA gently and by avoiding re-
peated pipetting or vortexing. For recombineering, we used
the target BAC pB-GK which contains 5′ and 3′ inverted
temrinal repeats (ITRs) of human adenovirus type 5 sep-
arated by a galK-Kan cassette encoding kanamycin and
galactokinase as selection markers (18). Note that this BAC
vector can be used for cloning of any human adenovirus
type 5 based genome. This target BAC was transformed into
SW102 cells and electro-competent bacteria were prepared.
Next 1.5 g of the adenovirus genome purified from virions
were transformed into these bacteria and  recombinases
were induced by heat shock at 42◦C for 15 min. For isola-
tion of single clones, bacteria were selected on agar plates
containing the respective selection markers.
If plasmids were used as a source for adenoviral genomes
as a second option, respective BACs were generated by
backbone-exchange, replacing the plasmid backbone with
the BAC-specific backbone. Especially, commercially avail-
able kits for adenovirus production deliver large plasmids
containing the major part of the adenoviral genome repre-
senting perfect sources for adenoviral DNA contained in
plasmids allowing access to the BAC-platform. Here, the
BAC-specific backbone containing a chloramphenicol re-
sistance marker gene was amplified by PCR utilizing primer
for generation of regions homologous to the 5′- and 3′-end
of adenovirus type 5 genome. The purified PCR-product
was transformed into SW102 bacteria with the plasmid
pHCAdV5-CMV/eGFP containing an adenoviral genome
of a HCAdV encoding GFP under the control of the CMV
promoter. Homologous recombination was induced and
bacteria with BACs containing the adenoviral genome were
isolated by positive selection for chloramphenicol resis-
tance. Note, that this method can be performed for any
adenoviral genome which was cloned as a plasmid. For
construct-specific PCR, primer pairs and their sequences
please refer to Supplementary Table S1.
Traceless genetic modification of hexon and fiber contained
in adenoviral genomes which were cloned as BACs
For construction of BACs encoding for hexon- and fiber-
modified adenoviral genomes we utilized cloning tech-
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niques based on BACs for which the basic principle was
described elsewhere (16). The BACs (BAC-AdV5 and BAC-
AdV5-HV) were transformed into SW102 E. coli. In paral-
lel, a galK/Amp cassette expressing galactokinase and am-
plicillin selection markers was PCR-amplified using pT-GA
as template with additional sequences at 5′ and 3′ ends ho-
mologous to the fiber and hexon gene sequences upstream
and downstream (for primer sequences please refer to Sup-
plementary Table S2). 1.5 g of respective PCR products
was transformed into SW102 containing pB-HV and af-
ter heat-shock activated homologous recombination and se-
lection for the ampicillin intermediate clone BAC-AdV5-
HV-HVR-galK/Amp was isolated. Subsequently, chimeric
hexon sequences generated by synthesis or regions of re-
spective adenoviral genomes coding for the surface domains
(SDs) of the hexon were PCR-amplified (for primer se-
quences please refer to Supplementary Table S2). Purified
PCR products were used for BAC cloning replacing the
galk/Amp sequence with chimeric hexon sequences by ho-
mologous recombination and single clones were isolated by
negative selection against galK. Next, all hexon-modified
helper-virus BACs were modulated replacing the stuffer
DNA in the E3 region by a reporter gene expression cas-
sette encoding a eGFP-firefly luciferase fusion protein un-
der the control of the CMV-enhancer/EF1 promoter. Pos-
itive clones were purified and used for reconstitution of re-
spective hexon-modified adenoviral helper-viruses (HV).
Reconstitution, amplification and purification of hexon- and
fiber-modified helper-viruses
HV were generated and amplified according to protocol
published previously (6). In brief, respective helper virus
BAC DNA was digested with PacI and transfected into
HEK293 cells with Fugene 6 (Roche). After cytopathic ef-
fect occurred 10–20 days post-transfection, cells were har-
vested and virus particles were released by three consecu-
tive freeze–thaw steps. HV was amplified by infection of in-
creasing numbers of HEK293 cells. For the final amplifica-
tion step, 4 × 108 HEK293 cells were infected and generated
HV particles were purified by two successive CsCl gradients.
For application in vitro and in vivo toxic CsCl solutions with
virus were exchanged with a physiological buffer by dialysis
and vector aliquots were stored at −80◦C until usage.
Recombination pipeline and cloning of the high-capacity ade-
novirus HCAdV5-2indsys
The recombination pipeline is a valuable tool if complex
DNA sequences are combined or if complex expression
systems need to be designed. Therefore, we developed a
novel recombination pipeline which allows combining vari-
ous DNA sequences using a cloning method which is solely
based on liquid bacteria culture. For a detailed protocol de-
scribing the recombination pipeline, refer to the supplemen-
tary material part. Here, we provide a step-by-step protocol
for a single cloning step within the recombination pipeline.
We used this method to generate a complex HCAdV for
transient cell marking to track differentiation or dediffer-
entiation processes. Toward that end two independent in-
ducible and tissue-specific expression systems were incorpo-
rated into the HCA genome resulting in the vector HCA-
2indsys. For details regarding all sequences contained in
HCA-2indsys, refer to the ‘Results’ section. The mifepris-
tone inducible system was based on the GeneSwitch Mam-
malian Expression Kit provided by Life Technologies.
All primers used for PCRs to amplify DNA sequences
used for the recombination pipeline to generate the vector
HCAdV5-2indsys are summarized in Supplementary Table
S1.
PCR
For all PCRs high-fidelity KOD Hot Start DNA Poly-
merase (Novagen, Darmstadt) was used except for ampli-
fication of the BAC-backbone, which was performed with
the PRECISOR polymerase (Biocat, Heidelberg). All used
primers and templates for respective PCRs are listed in Sup-
plementary Table S1. Specific primers for control PCRs to
verify hexon chimeras with precisely exchanged hypervari-
able regions (HVRs) were designed to bind to sequences of
HVR5 and HVR7 of respective hexon genes (for primer se-
quences, refer to Supplementary Table S2). Replacements of
the complete SDs were determined by primers used for gen-
eration of respective plasmids for expression in mammalian
cells (for primer sequences, refer to Supplementary Table
S2). For verification of sequences, vector genomes were se-
quenced by Eurofins MWG Operon (Ebersberg, Germany)
utilizing adequate primers listed in Supplementary Table
S2.
Cell culture
Human embryonic kidney cells (HEK293 cells) were cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum (FBS, PAA Lab-
oratories). One hundred sixteen cells used for production
of HCA were grown in modified Eagle’s medium (MEM)
supplemented with 10% FBS (PAA Laboratories) and hy-
gromycin B (100 g/ml). All media were also supplemented
with penicillin and streptomycin provided as a 100-fold con-
centrated stock solution (PAA Laboratories).
Luciferase assay
Quantification of firefly luciferase expression was per-
formed utilizing the Dual-Luciferase R© Reporter Assay Sys-
tem kit (Promega). In detail, HEK293 cells seeded in
six-well plates were infected with unmodified or hexon-
modified helper-virus (1 l/well). Forty-eight hours post-
infection, cells were washed with Dulbecco’s Phosphate-
Buffered Saline (DPBS) and harvested in 500 l passive lysis
buffer provided by the kit. Five microliters of the cell lysate
were mixed with 35 l luciferase assay reagent II, respec-
tively, and subsequently firefly luciferase activity was mea-
sured for 5 s at 492 nm utilizing a luminometer (Microlumat
Plus LB 96V, Berthold).
LacZ staining
HEK293 cells were seeded in six-well plates and transduced
with the capsid-modified HCA containing the lacZ expres-
sion cassette. Forty-eight hrous post-transduction cells were
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washed with Dulbecco’s phosphate buffered saline (PBS,
1×) and fixed with glutaraldehyd (0.8%). After 10 min, cells
were washed with Dulbecco’s PBS (1×) and stained with the
staining solution (1 mg/ml X Gal, 10 mM FeK4(CN)6, 10
mM FeK3(CN)6, 2 mM MgCl2) for 10 h.
Fluorescence microscopy
HEK293 cells were seeded in six-well plates and transduced
with the HCAdV containing the eGFP expression cassette.
Forty-eight hrous post-transduction eGFP expression was
detected with an inverse fluorescence microscope (Leica
DM IRB).
Construction of plasmids for chimeric hexon expression in
mammalian cells
For generation of plasmids encoding hexon chimeras with
completely exchanged surface regions, a master clone (pCI-
M) was constructed (Supplementary Figure S1). To gener-
ate this master clone, conserved 5′ and 3′ sequences were
amplified by PCR and subcloned into the vector pCR-
BluntII-Topo (Invitrogen) generating vectors pT-hex5-5′
with AarI and BglII binding sites at the 3′ end and pT-
hex5-3′ with BglII and BspQI binding sites at the 5′ end
(for primer sequences, refer to Supplementary Table S2).
Both vectors were cut with BglII and NotI and fragments
were ligated resulting in pT-M. Subsequently conserved
hexon regions were excised from pT-M with restriction en-
zymes SpeI and NotI and cloned into mammalian expres-
sion vector pCI (Promega) which was cut with XbaI and
NotI. Constructed vector pCI-M contained conserved 5′
and 3′ regions of human adenovirus type 5 hexon sepa-
rated by restriction enzyme binding sites AarI, BglII and
BspQI. Recognition sites for endonucleases type II AarI
and BspQI are directed toward the conserved hexon se-
quences. Digests with AarI and BspQI enabled cutting in
the conserved regions generating sticky ends and excision of
binding sites. For generation of hexon chimeras, sequences
of hexon genes encoded by viral genomes of respective ade-
novirus serotypes were amplified by PCR (for primer se-
quences, refer to Supplementary Table S2). PCR products
contain AarI binding sites at the 5′ end and BspQI binding
sites at the 3′ end, with respective cutting sites in the ampli-
fied hexon-specific region. Amplified sequences were sub-
cloned into the plasmid pCR-BluntII-Topo resulting in vec-
tors pT-hex5-SD4, -SD7, -SD12, -SD13 and -SD41. After
excising inserts with AarI and BspQI, fragments were sub-
cloned into the master plasmid pCI-M digested with AarI
and BspQI resulting in mammalian expression plasmids en-
coding for hexon chimera. To construct plasmid pCI-100K-
pr, vector pCI was linearized with SmaI and dephosphory-
lated with alkaline phosphatase. In parallel, the gene encod-
ing adenoviral 100K-protein was PCR-amplified utilizing
viral genomic DNA isolated from purified hAd5 particles
as template (for primer sequences, refer to Supplementary
Table S2). Purified PCR product was phosphorylated with
T4 polynucleotide kinase and blunt-end ligated with SmaI-
cutted pCI vector (T4 DNA Ligase) resulting in vector pCI-
100K-pr.
Synthesis of sequences encoding chimeric hexon surface do-
mains
For synthesis of chimeric hexon SDs sequences of HVRs
located within the human adenovirus type 5, hexon gene
sequence at positions 403–495 (HVR1), 562–582 (HVR2),
634–657 (HVR3), 742–783 (HVR4), 802–843 (HVR5), 913–
945 (HVR6) and 1255–1353 (HVR7) were precisely ex-
changed with respective sequences of human adenovirus
types 12, 41, 44, 48 and 50. Sequence synthesis was per-
formed by GeneArt (Regensburg, Germany) and for deliv-
ery sequences were incorporated into a standard vector.
Detection of Cre-mediated excision of the packaging signal
HEK293 cells and 116 HCAdV producer cells based on
HEK293 cells were seeded in six-well plates. At 90% con-
fluency, cells were infected with the helper virus contain-
ing a floxed packaging signal at MOI 3. Thirty-six hours
post transduction DNA was extracted from harvested cells,
purified with phenol–chloroform and precipitated with iso-
propanol. DNA samples were solved in water and used as
templates for PCR analysis (for primer sequences, refer to
Supplementary Table S1).
Western blot analysis
HEK 293 cells were seeded in 60 mm dishes and co-
transfected at 60% confluency with mammalian expression
plasmids pCI-100K-pr encoding adenoviral 100K-protein
and pCI-hex5-SD4, -SD7, -SD12, -SD13 and -SD41 for ex-
pression of the chimeric hexon protein. Seventy-two hours
post-transfection, cells were harvested in 200 l lysis buffer
(50 nM Tris–HCl pH 8.0, 150 nM NaCl, 1% NP-40) and
incubated for 30 min on ice. For western blot analysis, 5
l loading dye (5×) was added to 15 l cell lysate, respec-
tively, and subsequently boiled at 95◦C for 5 min or cooled
at 4◦C. Proteins were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) utilizing
a 10% SDS-polyacrylamide gel and transferred by semi-
dry blotting on a methanol-activated polyvinylidene diflu-
oride (PVDF) membrane. The membrane was treated over
night with blocking buffer (20 mM pH 7.5, 500 mM NaCl,
5% milk powder) and after three washing steps with TBST
(20 mM, Tris pH 7.5, 500 mM NaCl, 0.05% Tween, 0.2%
Triton-X100), the membrane was incubated for 1 h with the
polyclonal anti-adenovirus antibody PA1-7201 (Dianova,
final concentration 1:500) diluted in blocking buffer. Sub-
sequently, the membrane was washed three times and in-
cubated with the monoclonal peroxidase-conjugated rab-
bit anti-goat antibody (Jackson ImmunoResearch Labora-
tories Inc., final dilution 1:10 000) diluted with blocking
buffer. For protein detection, blots were washed three times,
ECL reagent (GE Healthcare) was added and peroxidase
activity detected according to manufacturer’s instructions.
Production of high-capacity adenoviral vectors (HCAdV)
Production of HCAdVs was performed in the producer cell
line 116 as described earlier (5,6). In brief, the HCAdV
genome was released from the BAC and DNA was trans-
fected into a 6 cm tissue culture dish with 116 cells. After
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24 h, cells are co-infected the helper virus and harvested
72 h after transfection. HCAdV capsids were released by
repeated freeze/thaw steps and used for three further am-
plification steps. In contrast, for large-scale amplification
10 confluent 15 cm tissue culture dishes of 116 cells were
transferred into 1 l of medium placed in a spinner flask.
Cells were grown for 5 days increasing the volume of culture
medium to up to 3 l. At day 5, cells were harvested by cen-
trifugation, resuspended in 150 ml medium, and co-infected
with 100% of the lysate derived from 8 × 107 116 producer
cells and AdNG163R-2 helper virus (5) (one infectious unit
per cell). Virus infection was performed at 37◦C on a mag-
netic stir plate for 2 h. Subsequently, medium (MEM sup-
plemented with 5% FBS) was added to a final volume of
2 l. Co-infected cells were harvested 48–72 h later for un-
modified and fiber-modified HV and 96 h later for hexon-
modified HV. Cells were lysed and released HCAs were pu-
rified by ion exchange columns or CsCl gradients.
Purification of adenoviral particles with ion-exchange
columns and CsCl gradients
Purification of small-scale AdV preparations was per-
formed with ion-exchange columns (Sartorius, Göttingen,
Germany) according to manufacturer’s instructions. To re-
duce the volume of cell lysate (80 ml) to the volume rec-
ommended by the manual, cells were harvested by centrifu-
gation before lysis and resuspended in 20 ml of the super-
natant. Large-scale amplified HCAs were purified by two
successive CsCl gradients (6). For in vitro and in vivo appli-
cations toxic CsCl solutions with virus were exchanged with
a physiological buffer by dialysis (6). Final vector aliquots
were stored at −80◦C until usage.
Determination of physical titers of hexon-modified helper-
viruses and sequencing
Detailed procedures to determine physical titers of an AdV
preparation were described elsewhere (6). In brief, for de-
termination of number of packaged viral particles (physi-
cal titer) we diluted 5 l of the vector preparation with 95
l Tris-EDTA (TE) buffer supplemented with 0.1% sodium
dodecylsulfate. After shaking for 30 min at 37◦C, OD260 was
measured five times and mean value was used to calculate
the physical titer. Sequencing for verification of modified
hexon regions was performed by Eurofins MWG Operon
(Ebersberg, Germany) utilizing sequencing primers (Sup-
plementary Table S2).
Flow cytometric analysis
HEK293 cells were seeded in six-well plates and in-
fected with unmodified or hexon-modified helper-virus (1
l/well). After 48 h incubation at 37◦C, cells were washed
with Dulbecco’s Phosphate-Buffered Saline (DPBS) and
treated with trypsin. Detached cells were harvested and re-
suspended in DPBS supplemented with 0.1% FBS. Subse-
quently, each sample was analyzed for eGFP expression by
flow cytometer FACS Canto II and data derived from 20
000 detected events were used for evaluation, respectively.
RESULTS
A BAC platform for cloning and traceless genetic modifica-
tion of adenoviral DNA
Currently used methods for genetic manipulation of ade-
noviruses are work-intensive and time-consuming and are
dependent on complex construction of intermediate clones
containing either respective endonuclease binding sites or
long homologous sequences. Here, we adopted a differ-
ent recombination method which was first described for
modulation of BACs (16). For efficient cloning of AdVs,
this recombineering technology only relies on short homol-
ogy arms (50 bp) which can be added to a PCR prod-
uct using respective PCR primers. We explored recombi-
neering based on a positive/negative selection system as an
elegant method for genetic engineering allowing seamless
genetic modification of adenoviral genomes contained in
BACs (16,19–20). This unique BAC-platform enables ac-
cess to different sources of adenovirus DNA such as pu-
rified virions or plasmids containing full-length adenovirus
DNA molecules (Figure 1a). The cloning strategy is based
on an intermediate BAC which contains galK flanked by
respective homologous regions and in the presence of the
linear adenoviral DNA homologous recombination occurs
in SW102 bacteria. The same recomineering strategy can
be utilized for traceless genetic modification of adenoviral
genomes as schematically shown in Figure 1b. In a first step
the selection marker including galK and an antibiotic resis-
tance gene (e.g. ampicillin, kanamycin, zeocin) is PCR am-
plified using PCR primers which will flank the PCR prod-
uct by homologous regions which are also represent in the
target BAC. During homologous recombination, these se-
lection markers will be inserted into the intermediate BAC.
In the next step, a second PCR product containing the de-
sired DNA to be inserted into the BAC flanked by respective
homologous regions can then replace the selection marker
using negative selection based on galK (Figure 1b).
To show integrity of the recombineering system, we ex-
emplify access to adenoviral DNA by direct cloning of an
E1/E3-deleted adenoviral DNA molecule which was iso-
lated from purified virions (Figure 2a). For that purpose,
the target BAC pB-GK, which contains 5′ and 3′ ITRs of
human adenovirus type 5 separated by a galK-Kan cas-
sette encoding kanamycin and galactokinase as selection
markers (18), was transformed into SW102 E. coli. Next,
purified adenoviral DNA molecules were transformed into
these bacteria and  recombinases were induced by heat
shock at 42◦C for 15 min. For isolation of single clones,
bacteria were selected on agar plates containing the respec-
tive selection markers. The resulting BAC (BAC-AdV5) was
used for further traceless genetic modification. We intro-
duced capsid modifications resulting into the two cloned
capsid–chimeric recombinant AdVs BAC-AdV5-Fib35 and
BAC-AdV5-HVR48 (Figure 2b). BAC-AdV5-Fib35 con-
tains fiber knob domains from human adenovirus type
35 (species B) allowing transduction of cells, which are
not accessible for vectors with unmodified fibers such as
hematopoietic stem cells (11,21). BAC-AdV5-HVR48 con-
tains precisely exchanged HVRs from human adenovirus
type 48 (species D) in the major capsid protein hexon and
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Figure 1. The galK technology for cloning of recombinant adenoviral genomes contained in BACs. (a) Access to adenoviral genomes from different sources.
DNA extracted from purified adenoviral particles or plasmids can be used as a source of adenoviral genomes. Isolated viral DNA was transformed into
SW102 bacteria containing an intermediate BAC containing the 5′- and 3′- inverted terminal repeats (ITRs) of an adenoviral genome, a chloramphenicol
resistance (CmR) and the selection marker gene galaktokinase (galK) allowing positive and negative selection. In addition, this minimal BAC contains two
homologous regions (H1 and H2) and after induction of homologous recombination of 5′- and 3′-ends, bacteria with the BAC containing the adenoviral
genome were isolated upon negative selection against galK. (b) Traceless modification of adenoviral genomes. A BAC containing a chloramphenicol
resistance gene and the adenoviral genome and a PCR product (PCR I) with galK allowing positive and negative selection and another positive selection
marker (S) for instance kanamycin or ampicillin are con-transformed into SW102 bacteria. The PCR product is flanked by homologous regions (H1 and
H2) also contained in the adenoviral genome and after recombineering (recombineering I) the resulting intermediate BAC is used for the next step. A
second PCR product (PCR II) flanked by the homologous regions H1 and H2 is used for the second recombineering (recombineering II) step for which
negative galK selection is used leading to the final BAC.
it was shown that this capsid modification escapes neu-
tralizing anti-adenoviral antibodies directed against hu-
man adenovirus type 5 (10). For incorporation of fiber
and hexon chimeric sequences, we transformed BAC-AdV5
into SW102 E. coli and for homologous recombination a
PCR fragment containing the galK/Amp cassette express-
ing galactokinase and amplicillin selection markers was
PCR-amplified with additional sequences at 5′ and 3′ ends
homologous to respective fiber and hexon gene sequences.
DNA sequences contained in the BACs were verified by
PCR and diagnostic restriction enzyme pattern (Figure 2b)
and respective viruses (AdV5-Fib35 and AdV5-HVR48)
could be reconstituted in HEK293 cells.
A novel recombination pipeline for generation of complex
adenoviral vectors
To further exploit our BAC-platform, we used capsid
chimeric rAdVs as HV which carry a floxed packaging sig-
nal required for production of capsid modified HCAdVs en-
coding ß-galactosidase (Figure 3a). Respective HVs (AdV5-
HV, AdV5-HV-Fib35, AdV5-HV-HVR48) were produced
at normal titers and excision of the packaging signal was
shown by PCR (Figure 3a). Subsequently, a HCAdV en-
coding ß-galactosidase was produced in the HCAdV pro-
ducer cell line (116 cells) and functionality of the produced
HCAdV (HCAdV5-lacZ, HCAdV5-Fib35-lacZ, HCAdV5-
HVR48-lacZ) was demonstrated by transgene expression
after infection (Figure 3a).
To enable genetic modification of HCAdV genomes
which allow packaging of transgenes of up to 36 kb,
we cloned a HCAdV genome as BAC by backbone ex-
change (Figure 3b). We used a plasmid carrying a HCAdV
genome and simply exchanged the plasmid backbone with
a BAC backbone which was amplified by PCR (Fig-
ure 3b). After recombineering integrity of the cloned BAC
(BAC-HCAdV5-CMV/eGFP) was confirmed by diagnos-
tic restriction enzyme pattern and the resulting HCAdV
(HCAdV5-CMV/eGFP) was produced using a commonly
used HV (AdV5-HV) based on adenovirus type 5 (Fig-
ure 3b).
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Figure 2. Cloning of E1/E3-deleted adenoviral genomes from virions (access) and traceless hexon and fiber genetic modification. (a) Cloning of a first
generation E1/E3-deleted adenoviral genome from purified virions. Verification of the cloned adenovirus genome from purified virus particles as BAC
showing the expected DNA fragmentation pattern after EcoRV restriction enzyme digest of isolated BAC-DNA. (i) Intermediate BAC containing galK,
(ii) final BAC (BAC-AdV5) with cloned adenovirus genome. (b) Homologous recombination for generation of fiber- and hexon-modified E1/E3-deleted
adenoviral genomes. For generation of the intermediate fiber-modified adenovirus BAC (BAC-AdV5-Fib-galK/Amp) and the intermediate hexon-modified
adenovirus BAC (BAC-AdV5-HVR-galK/Amp), the sequence encoding the fiber knob and the hexon-derived HVRs were replaced by inserting the ampi-
cillin resistance gene (Amp) as a positive-selection marker and galactokinase (galK) as a positive/negative-selection marker. For traceless modification,
PCR-amplified DNA-fragments containing the coding sequence for the fiber knob from adenovirus type 35 and a synthesized DNA-fragment with HVRs
precisely replaced with respective sequences of adenovirus type 48 were incorporated replacing the positive/negative selection marker combination. In-
tegrity of final BACs (BAC-AdV5-Fib35 and BAC-AdV5-HVR48) was verified by EcoRV restriction enzyme digests and specific PCRs amplifying the
respective modified capsid regions. (i) BAC-AdV5; (ii) BAC-AdV5-Fib-galK/Amp; (iii) BAC-AdV-fib5/35; (iv) original BAC-AdV5; (v) BAC-AdV5-HVR-
galK/Amp; (vi) BAC-AdV-hex5/48. PCRs specific for unmodified and modified fiber (Fib5) and hexon (HVR5) genes amplify 1.8 and 0.5 kb fiber- and
hexon-specific DNA fragments, respectively. After transfection of the linearized constructs into HEK293 cells, viruses (AdV5-Fib35 and AdV5-HVR48)
were rescued.
To design complex expression systems to be delivered by
AdV we established a novel DNA recombination pipeline
only based on liquid bacteria culture enabling smooth com-
bination of DNA sequences. This pipeline is based on itera-
tive BAC cloning steps successively incorporating sequences
coupled with alternating positive selection markers into the
same BAC (Figure 4a). For that purpose, a PCR prod-
uct is generated containing a positive selection marker and
the first sequence of interest and transformed into bacte-
ria with the target BAC. The second PCR product contains
another positive selection marker and the second sequence
of interest flanked by sequences, which are homologous to
5′- and 3′-sequences of the first selection marker. Homolo-
gous recombination and selection for the second selection
marker enables efficient site-directed incorporation of the
second sequence of interest into the BAC (Figure 4a and
Supplementary Material section). This process can be re-
peated for fast combination of sequences within a single
BAC. In addition, DNA can be isolated from liquid culture
and utilized as template for PCR amplification. Therefore,
sequences combined by iterative homologous recombina-
tion steps could be amplified by PCR and incorporated into
another BAC. Combinations of sequences with alternating
positive selection markers, which are necessary for the re-
combination pipeline, are either present in adequate plas-
mids or generated by subcloning, overlapping PCR or lig-
ation of PCR-amplified sequences. Furthermore, iterative
PCRs can be used to attach small sequences such as min-
imal polyadenylation signals or minimal internal riboso-
mal entry sites (IRES), to the amplified template-derived se-
quences. Therefore, the recombination pipeline enables con-
struction of complex genome fragments by smooth modula-
tion of basic BACs utilizing repetitive cloning steps without
the need of isolation of intermediates.
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Figure 3. Exploring the BAC platform for cloning and production of HCAdV. (a) Generation of capsid-modified HV with a floxed packaging signal
using the BAC platform. A floxed packaging signal (loxP//loxP) was inserted into unmodified and capsid-modified BACs (BAC-AdV5, BAC-AdV5-
Fib35, BAC-AdV5-HVR48) (see also Figure 2) by recombineering resulting into BAC-AdV5-HV, BAC-AdV5-HV-Fib35, and BAC-AdV5-HV-HVR48.
Respective helper viruses were produced and excision of the packaging signal was shown by PCR. Agarose gels show PCR products after infection with
HVs of cells either lacking Cre recombinase (−) or stably encoding Cre recombinase (+). HVs were used to produce a capsid modified HCAdV (HCAdV5-
CMV-lacZ) lacking all viral coding sequences which contains a transgene expressing ß-galactosidase (lacZ) under the control of the cytomegalovirus (CMV)
promoter. The lower panel shows ß-galactosidase of cells infected with unmodified (HCAdV-lacZ) and capsid-modified HCAdVs (HCAdV5-Fib35-lacZ
and HCAdV5-HVR48-lacZ). ITR: adenoviral inverted terminal repeats, M: DNA ladder. (b) For available plasmids containing adenoviral genomes (e.g. the
HCAdV genome), respective BACs can be generated by backbone-exchange, replacing the plasmid backbone with the BAC-specific backbone containing a
chloramphenicol resistance marker gene (CmR). Here, the BAC-specific backbone was amplified by PCR utilizing primers to generate regions homologous
to the 5′- and 3′-end of adenoviral genome (HR1 and HR2). For recombineering the purified PCR-product was transformed into SW102 bacteria with the
plasmid containing the adenoviral genome. Bacteria with BACs containing the adenoviral genome were isolated by positive selection for chloramphenicol
resistance. The left agarose gel shows amplification of the PCR-product used for transformation (i). Successful backbone-exchange was verified by PmeI
digest (PmeI restriction enzyme recognition sites are indicated by white arrows) of the plasmid (ii) and the generated BAC (iii) containing the genome of a
high-capacity AdV genome with an eGFP expression cassette (BAC-HCAdV5-CMV/eGFP). Note that the 700 bp band after PmeI digest is not visible on
the agarose gel. Fragments specific for respective backbones are marked with red horizontal arrows. The corresponding HCAdV (HCAdV5-CMV/eGFP)
was produced using the helper virus HV-AdV5 and infection of HEK293 cells with the purified HCAdV resulted in eGFP expression.
Here, we used this recombination pipeline to generate a
complex HCAdV genome for transient cell marking and
to track differentiation or dedifferentiation processes. Two
independent inducible and tissue-specific expression sys-
tems were incorporated into the HCAdV genome result-
ing into the BAC and corresponding viral vector BAC-
HCAdV5-2indsys and HCAdV5-2indsys, respectively (Fig-
ure 4b). The first tissue-specific inducible system consists of
the switch protein under control of a liver-specific promoter
construct containing the apolipoprotein E (ApoE) enhancer
element in combination with the human 1-antitrypsin
(hAAT) promoter and the Renilla luciferase gene under
control of a hybrid promoter. This hybrid promoter con-
tains the Saccharomyces cerevisiae GAL4 upstream activat-
ing sequences (UAS) linked to an adenoviral TATA box
derived from the early adenoviral gene E1b (Figure 4b).
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Figure 4. Generation of the complex high-capacity AdV HCAdV5–2indsys utilizing the novel recombination pipeline. (a) Recombination pipeline for
cloning of complex transgenes solely based on liquid bacteria culture. Different DNA sequences can be sequentially combined using different selection
markers (e.g. A: ampicillin, K: kanamycin). As a starting source of DNA a plasmid containing the DNA fragment of interest can be used and PCR
performed containing an additional selection marker. In the next step, an additional DNA fragment can be added by insertion of a different selection
marker. Using this method, complex DNA sequences can be assembled step by step. After recombineering, these assembled DNA sequences can get
access to the BAC-platform or other applications. (b) Strategy for generation of the complex high-capacity adenovirus genome HCA-2indsys. The DNA
recombination pipeline was used to generate four intermediate BACs containing different expression cassettes. Please note that positive selection markers
are not shown. For each intermediate BAC, two sequences were combined, respectively (steps Ia-IVa and Ib-IVb). Furthermore, additional sequences
were generated by extension of the respective PCR products (IIb: pA-signal, IIIa: Tet-Operator, IVa: IRES). Subsequently, expression cassettes encoded
by the intermediate BACs were amplified by PCR incorporated into BAC-HCAdV5-CMV/eGFP resulting in the BAC BAC-HCAdV5–2indsys (steps I–
IV). DNA sequences contained in the final BAC BAC-HCAdV5–2indsys are shown at the bottom. dsRed: red fluorescent protein, Tet-Rep: Tet-repressor,
CMV-Pr.: cytomegalovirus promoter, Oct4: octamer transcription factor binding factor 4, eGFP: green fluorescent protein, Fluc: firefly luciferase, hRlus:
renilla luciferase, Gal4: regulatory protein Gal4, hAAT-Pr.: alpha-1-antitrypsin promoter, switch: switch protein. (c) A specific PCR detecting the respective
cloned DNA fragments was performed. DNA was isolated from liquid cultures of intermediate clones B-Ib–B-IVb and the final BAC BHCA-2indsys. Sizes
of PCR products: Ia: 2.0 kb, Ib: 2.5 kb, IIa: 1.6 kb, IIb: 2.4 kb, IIIa: 4 kb, IIIb: 4.5 kb, IVa: 2.1 kb, IVb: 3.5 kb. (d) The final BAC BAC-HCAdV5-2indsys
was analysed for inserted sequences by transgene specific PCRs (I–IV). (e) Functionality of complex vector genomes exemplified by HCAdV5-2indsys with
multiple transgenes generated by the recombination pipeline. The HCAdV encodes dsRed (right panel) and mifepristone-inducible expression expressed
as relative light units (RLU) in hepatocytes is shown in the left panel.
The fusion protein pSwitch consists of the yeast GAL4
DNA binding domain (DBD), a truncated human proges-
terone receptor ligand binding domain (hPR-LBD), and the
human p65 activation domain (AD) from NF-B. There-
fore, transduced hepatocytes express the switch protein and
upon administration of mifepristone this protein is acti-
vated mediating specific transcription of the Gal4-promoter
controlled Renilla luciferase. The second inducible system
was realized by two expression cassettes encoding the Tet-
suppressor protein under control of the CMV-promotor
as well as an eGFP/Firefly luciferase fusion protein under
control of the endogenous oct-4 promoter and four Tet-
operator sequences (Figure 4b). Thus, after transduction
of cells expressing the stem cell-specific transcription fac-
tor oct4, this factor can bind to the oct4-promoter. How-
ever, transcription is blocked by binding of highly expressed
Tet-suppressor proteins to the Tet-operator sequences. Only
in presence of doxycycline, which interacts with the Tet-
suppressor protein and therefore inhibits binding to Tet-
operator sequences, the fusion protein eGFP/FLuc is tran-
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Figure 5. Incorporation of chimeric hexon genes into E1 and E3 deleted adenoviral HV genomes embedded in BACs. (a) A scheme of precise exchanges
of HVRs 1–7 and SDs in the adenoviral capsid is shown. DE1, FG1 and FG2 display extended loops. The packaging signal is flanked by Cre recombinase
recognition sites (loxP//loxP) and the HV contains a bicistronic transgene encoding firefly luciferase (Fluc) and eGFP. (b) Hexon-modified helper-
virus genomes were generated by traceless modulation of a BAC utilizing homologous recombination based on the PCR I based product which was
flanked by homologous regions HR1 and HR2. The positive–negative selection marker cassette containing galactokinase and ampicillin (galK/Amp) was
incorporated into BAC-AdV5-HV containing the helper-virus genome replacing the region encoding SDs of the hexon gene. Intermediate clone BAC-
AdV5-HV-HVR-galK/Amp was isolated after selection with ampicillin. Subsequently, PCR-amplified chimeric hexon sequences (sequences for chimeric
hexon genes containing HVRs and SDs from other adenovirus types) replaced the selection cassette and final BACs were obtained upon selection against
galactokinase. (c) Incorporation of chimeric hexon sequences was verified by specific PCRs detecting the respective chimeric hexon. The original BAC-
AdV5-HV was used as negative control. (d) Contaminations with unmodified helper-virus BACs were excluded by PCR specifically detecting the SDs of
the original hexon from adenovirus type 5. Unmodified BAC-AdV5-HV as well as the revertant BAC-AdV5-HV-HVR5 were used as a positive control.
M: 1 kb DNA ladder.
scribed efficiently. In addition, fluorescence marker dsRed
was coupled to constitutive expression of Tet-repressors
via an IRES enabling detection of transduction rates. PCR
products used for the recombination pipeline are shown in
Figure 4c and the final BAC (BAC-HCAdV5–2indsys) was
also verified by PCR BAC-specific PCRs (Figure 4d). Af-
ter reconstitution of the respective virus HCAdV5-2indsys,
we checked the liver-specific inducible system contained in
the vector. As expected we found that transduced hepato-
cytes express the switch protein and upon administration
of mifepristone this protein is activated mediating specific
transcription from the Gal4-promoter (Figure 4e).
High-throughput generation of hexon-modified adenoviral
vectors based on recombineering
Already a limited number of single hexon-modifications
had a major impact on understanding adenovirus biology
and uptake of AdV virions in vivo (10,22). However, over
the recent years this research field was limited due to the
lack of a reliable method to introduce hexon-modifications
in a high-throughput manner. Thus to exploit the full poten-
tial of the adenoviral recombineering technology, chimeric
hexon gene regions were generated in which either the
HVRs were precisely exchanged or complete SDs were re-
placed by SDs derived from other human adenovirus types
(Figure 5a). We synthesized coding sequences of hexons
with HVRs precisely exchanged with respective sequences
of human adenovirus types 12, 41, 44, 48 and 50. In par-
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Figure 6. Rescue and characterization of hexon chimeric adenoviruses. (a) Summary of cloned hexon chimeric helper viruses and the adenovirus subgroup
these hexon modifications belong to. (+): Rescue of adenovirus successful; (−) rescue of recombinant unsuccessful. (b) Characterization of final preparations
of reconstituted hexon-modified helper-viruses. Vector genomes derived from purified viral particles of final vector preparations of AdV5-HV-HVR12,
AdV-HV-SD12 and AdV-HV-SD4 were analyzed by PCRs specific for respective hexon-modification to verify chimeric hexon genes. The lower panel
shows PCR reactions specific for unmodified hexon gene to exclude contamination. (c) Physical titers (viral particles per l) for these vector preparations.
(d) Functionality of reporter gene eGFP-FLuc was tested by infection of HEK293 cells (1 l each). eGFP expression was determined by flow cytometry
and (e) by luciferase assay for firefly luciferase activity.
allel, a cloning system based on type II endonuclease was
used to generate chimeric hexon genes replacing complete
hexon SDs with respective sequences from human aden-
ovirus types 4, 7, 12, 13 and 41 (Supplementary Figure S1).
These chimeric hexon proteins form trimers in the pres-
ence of adenoviral chaperone 100K-protein (Supplemen-
tary Figure S1) which is a prerequisite for virion assembly.
All modified chimeric hexon genes were incorporated into
the genome of a E1/E3-deleted adenovirus type 5 genome
by DNA recombineering (Figure 5b). To show that fur-
ther genetic modification in subsequent steps is feasible,
we exemplified this by inserting a marker gene expression
cassette encoding firefly luciferase and eGFP into the E3
region of the hexon modified AdVs. The cloning strategy
and characterization of the final BAC for virus reconsti-
tution is exemplarily shown for the hexon modified AdV5-
HV-HVR48 in Supplementary Figure S2a and Sb. Further-
more, the cloned hexon-modified viruses contained a floxed
packaging signal enabling production of respective hexon-
modified HCAdVs. Final constructs were analyzed by re-
striction enzyme digests resulting in a specific pattern of
fragments of respective viral genomes (Supplementary Fig-
ure S2c). Furthermore, incorporated hexon modifications
were verified by PCRs specific for respective modifications
(Figure 5c) and in parallel contaminations with unmodi-
fied helper-virus BACs were excluded by PCR analysis with
primers specific for the unmodified hexon gene (Figure 5d).
For reconstitution of hexon modified viruses, linearized
BACs with chimeric hexon-modified adenoviral genomes
were transfected into HEK293 cells. We successfully res-
cued hexon-modified viruses AdV5-HV-HVR12, AdV5-
HV-SD12 and AdV5-HV-SD4 (Figure 6a). We checked
stability of hexon-modified genomes after virus amplifica-
tion and purification by PCR specifically detecting hexon
chimeras (Figure 6b) and we verified hexon sequences by
sequencing. Viral particle numbers (Figure 6c) and infec-
tious titers of final vector preparations were comparable
to unmodified virus as demonstrated by measuring eGFP
expression and luciferase expression levels after infection
(Figure 6d and e).
DISCUSSION
Here we introduced a novel BAC platform utilizing trace-
less cloning strategies enabling smooth design of arbi-
trary DNA-modified adenoviruses. We demonstrate that
this BAC cloning technology is a suitable method for rapid
assembly of recombinant adenoviral genomes containing
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Figure 7. Rapid adenovirus cloning platform for generation of arbitrary genetically modified adenoviruses in a high-throughput manner. Shown is the
BAC-platform allowing (i) access to different sources of adenovirus DNA, (ii) arbitrary traceless genetic modification of cloned viral genomes and (iii)
further modifications at the 5′ and 3′ ends of the adenoviral genome, at the early adenoviral genes E1 and E3 regions, within a HCAdV genome and cloned
HV used for production of high-capacity AdVs. After production (iv) and characterization of recombinant adenoviruses, these can be further modified
using the BAC-pipeline from the beginning. The cloning procedure is based on different selection markers such as galK (G) which can be used for positive
and negative selection and other resistance genes such as ampicillin (A). Cloned recombinant adenoviruses can either be used for virus production or
if desired further modified using the BAC-platform. Access to different sources of adenovirus DNA is exemplified by cloning of HV from adenovirus
virions and HCAdV from a plasmid. Traceless modification is exemplified by hexon-modification (HVR48: hexon from adenovirus types 5 with HVRs
from adenovirus type 48), fiber-modification (Fib35: fiber from adenovirus type 5 with fiber knob from adenovirus type 35), and modification of HCAdV
by adding a transgene. Further modification of the adenovirus genome is exemplified by replacing E3 with a transgene encoding eGFP and firefly luciferase
(Fluc) and by adding an additional transgene to the HCAdV genome.
a variety of mutations at a single genomic location (Fig-
ure 7). A flow chart of the technology and a general time line
are schematically shown in Supplementary Figure S3. This
allows switching between different adenovirus types such
as cloned wild type viruses, E1- and E1/E3-deleted AdVs,
HCAdVs including their helper viruses for HCAdV produc-
tion, and oncolytic rAd used in biotechnology, preclinical
and clinical studies.
Compared to conventional cloning techniques our re-
combineering platform is less time-consuming and chal-
lenging construction of intermediate clones with DNA
flanked by long homologies or endonuclease binding sites
can be avoided. In combination with the recombination
pipeline the adenoviral genome can be directly modified
in a stepwise and traceless manner. Commonly used tech-
niques for generation of recombinant adenoviral genomes
are based on either rare endonucleases or homologous re-
combination relying on long homologous sequences (>200
bp) (15) in mammalian cells or bacteria of E. coli strain
BJ5183 (12–14). In contrast our recombineering technology
allows efficient homologous recombination based on small
homologous regions (<50 bp), which can be generated by
PCR utilizing appropriate primers. As another major ad-
vantage our technique allows getting direct access to com-
plete adenoviral genomes which can be cloned as BACs in
a single step. In the present study we focused on cloning
and engineering of human adenovirus genomes. However,
it needs to be emphasized that our technology can also be
used to clone adenoviruses from other species.
Furthermore, a newly invented recombination pipeline
was demonstrated to allow complex modulations of high-
capacity adenoviral genomes. It is of note that utilization
of the recombination pipeline could be limited by the size
of the PCR product. However, it was shown that ampli-
fication of PCR products of up to 10 kb is feasible when
utilizing specific proof-reading polymerases. Nevertheless,
larger sequences such as the dystrophin gene used for treat-
ment of patients with muscular dystrophy (23) could be
split in two fragments and sequentially incorporated into
the target BAC. Furthermore, incorporation of sequences
with homologies to the target BAC smaller than 50 bp ap-
peared to be challenging due to unspecific recombination
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events. Especially with respect to sequences often used in
expression cassettes such as polyadenylation signals and
some promoter- or enhancer-elements, careful planning of
the construction procedure is essential to avoid problems
caused by this phenomenon. In contrast, two homologous
regions of more than 500 bp, which were part of the same
BAC, were stable even after heat-induction of recombinases
(data not shown).
To reconstitute hexon-modified HV, genomes were ex-
cised from respective HV BACs and HEK293 cells were
transfected with linear adenoviral DNA. After cytopathic
effect was observed, cells were harvested and used for fur-
ther amplification steps. However, reconstitution remained
challenging, because no stable protocol could be established
and no clear bottleneck could be identified for the reconsti-
tution procedure. Purity of linearized viral genome DNA
utilized for transduction of adenovirus producer cells as
well as high transfection efficiencies may represent critical
factors. Nevertheless, several viral vectors with exchanged
HVRs as well as with completely replaced SDs were re-
constituted, indicating that not the size of the inserted se-
quence but rather the protein folding of the chimeric hexon
could play a crucial for reconstitution (24). In concor-
dance with this assumption, complete trimerization of pro-
tein chimeras in cell culture demonstrated, that steric hin-
drance did not inhibit early assembly steps and that hexon
trimer stability was not significantly reduced. Furthermore,
serotype-specific HVR sequences are similar in size in com-
parison with the original sequence derived from human ade-
novirus type 5. Therefore, steric hindrance causing inhibi-
tion of interactions between hexon trimers and neighbor-
ing hexon trimers or other proteins of the capsid shell is un-
likely.
In summary, we introduced improved techniques based
on recombineering allowing arbitrary genetic modification
of AdVs. We developed a method which allows introduc-
ing any traceless genetic modification (insertion, deletion
or replacement of viral DNA) at any location of the ade-
novirus genome. In this study we cloned numerous AdVs
with different features underlining the potential for high-
throughput applications. Our method enables efficient gen-
eration of AdV for applications in biotechnology and in
therapeutic and vaccination approaches. It may pave the
way towards finding novel insights into adenovirus biology
and developing improved therapeutic AdVs including AdVs
for genome editing based on HCAdVs (25). Therefore, new
resources are opened for current approaches in gene ther-
apy or vaccination as well as for new areas like stem cell
technology, tissue engineering or basic research.
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